Effect of Initial Combination Therapy With Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients With Type 2 Diabetes

Goldstein, Barry J., Feinglos, Mark N., Lunceford, Jared K., Johnson, Jeremy, Williams-Herman, Debora E., for the Sitagliptin 036 Study Group·2007·Diabetes Care

DOI 10.2337/dc07-0627

Cited by (510)

Items 101–200 of 510

Effects of LX4211, a Dual SGLT1/SGLT2 Inhibitor, Plus Sitagliptin on Postprandial Active GLP-1 and Glycemic Control in Type 2 Diabetes
Brian Zambrowicz, Zhi‐Ming Ding, Ike Ogbaa, Kenny Frazier, Phillip Lee Banks, Anne Turnage, Joel P. Freiman, Melinda G. Smith, Dennis A. Ruff, Arthur Sands et al. · 2013 · Clinical Therapeutics
Efficacy and Safety Profile Evaluation of Acarbose Alone and in Association With Other Antidiabetic Drugs: A Systematic Review
Derosa, Giuseppe, Maffioli, Pamela · 2012 · Clinical Therapeutics
Dipeptidyl peptidase‐4 inhibitors and preservation of pancreatic islet‐cell function: a critical appraisal of the evidence
Renate E. van Genugten, Daniël H. van Raalte, Michaëla Diamant · 2011 · Diabetes Obesity and Metabolism
Efficacy and safety of incretin-based therapies: Clinical trial data
John Raymond White · 2009 · Journal of the American Pharmacists Association
Recent advances in the management of type 2 diabetes mellitus: a review
B. T. Srinivasan, Janet Jarvis, Kamlesh Khunti, Melanie Jane Davies · 2008 · Postgraduate Medical Journal
Cardiovascular safety of anti-diabetic drugs
Rekha B. Kumar, David M. Kerins, Thomas Walther · 2015 · European Heart Journal - Cardiovascular Pharmacotherapy
Preservation of β-cell function by targeting β-cell mass
E DEKONING, Susan Bonner‐Weir, Ton J. Rabelink · 2008 · Trends in Pharmacological Sciences
Predictors of response to dipeptidyl peptidase‐4 inhibitors: evidence from randomized clinical trials
Matteo Monami, Francesco Cremasco, Caterina Lamanna, Niccolò Marchionni, Edoardo Mannucci · 2011 · Diabetes/Metabolism Research and Reviews
The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes*†
Wenying Yang, Yanfen Guan, Yue Shentu, Zhi Li, Amy O. Johnson‐Levonas, Samuel S. Engel, Keith D. Kaufman, Barry J. Goldstein, Maria Alba · 2012 · Journal of Diabetes
Overview of metformin: special focus on metformin extended release
Shamsa Ali, Vivian Andrew Fonseca · 2012 · Expert Opinion on Pharmacotherapy
β-cell neogenesis: A rising star to rescue diabetes mellitus
Fanglin Niu, Wenxuan Liu, Yuanyuan Ren, Ye Tian, Wenzhen Shi, Man Li, Yujia Li, Yuyan Xiong, Qian Lü · 2023 · Journal of Advanced Research
Initial Combination Therapy for Type 2 Diabetes Mellitus: Is It Ready for Prime Time?
Bernard Zinman · 2010 · The American Journal of Medicine
DPP-4 inhibitor therapy and bone fractures in people with Type 2 diabetes – A systematic review and meta-analysis
Jil Mamza, Carol Marlin, Cai Wang, Kamal Chokkalingam, ISKANDAR RAUF IDRIS · 2016 · Diabetes Research and Clinical Practice
The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes
Hajime Maeda, Akira Kubota, Yasushi Tanaka, Yasuo Terauchi, Ikuro Matsuba · 2011 · Diabetes Research and Clinical Practice
Fixed-Dose Combinations for Treatment of Type 2 Diabetes Mellitus
Lawrence Blonde, Zinnia T. San Juan · 2012 · Advances in Therapy
Oral antidiabetic drug metabolism: pharmacogenomics and drug interactions
Andreas Holstein, Winfried Beil · 2009 · Expert Opinion on Drug Metabolism & Toxicology
Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes
Nasser E. Mikhail · 2008 · Expert Opinion on Investigational Drugs
Comparison of Glucose Lowering Effect of Metformin and Acarbose in Type 2 Diabetes Mellitus: A Meta-Analysis
Shuyan Gu, Jihao Shi, Zhiliu Tang, Monika S. Sawhney, Huimei Hu, Lizheng Shi, Vivian Andrew Fonseca, Hengjin Dong · 2015 · PLoS ONE
Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis
Subodh Verma, Ronald Goldenberg, Deepak L. Bhatt, Michael E. Farkouh, Adrian Quan, Hwee Teoh, Kim Alexander Connelly, Lawrence A. Leiter, Jan O. Friedrich · 2017 · CMAJ Open
Metformin monotherapy for adults with type 2 diabetes mellitus
Filip Gnesin, Anne Cathrine B. Thuesen, Lise Katrine Aronsen Kähler, Sten Madsbad, Bianca Hemmingsen · 2020 · Cochrane Database of Systematic Reviews
Restricting carbohydrates at breakfast is sufficient to reduce 24-hour exposure to postprandial hyperglycemia and improve glycemic variability
Courtney R. Chang, Monique E. François, Jonathan P. Little · 2019 · American Journal of Clinical Nutrition
Incretin‐based therapies
Anthony H. Stonehouse, Tamara Darsow, David G. Maggs · 2011 · Journal of Diabetes
Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18‐week randomized, double‐blind, placebo‐controlled phase III trial with a 34‐week active‐controlled extension
Anthony H Barnett, Sakshi Patel, Ruth Harper, Robert Toorawa, Sandra Thiemann, Maximilian von Eynatten, H.J. Woerle · 2012 · Diabetes Obesity and Metabolism
Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes
Carolina Solis‐Herrera, Curtis L. Triplitt, José de Jesús Garduño‐García, John Adams, Ralph A. DeFronzo, Eugênio Cersósimo · 2013 · Diabetes Care
Clinical Application of Incretin-Based Therapy: Therapeutic Potential, Patient Selection and Clinical Use
David M. Kendall, Robert M Cuddihy, Richard M. Bergenstal · 2009 · European Journal of Internal Medicine
Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus
Sung‐Ho Kim, Jung-hwa Yoo, Woo Je Lee, Cheol‐Young Park · 2016 · Diabetes & Metabolism Journal
Predictors and Consequences of Severe Hypoglycemia in Adults with Diabetes - A Systematic Review of the Evidence
Hanna E. Bloomfield, Nancy L. Greer, David R. Newman, Roderick H. MacDonald, Maureen H. Carlyle, PATRICK J. FITZGERALD, Indulis R. Rutks, Timothy J Wilt · 2012
Saxagliptin: A Clinical Review in the Treatment of Type 2 Diabetes Mellitus
Deanna S. Kania, Jasmine D. Gonzalvo, Zach Weber · 2011 · Clinical Therapeutics
Type 2 Diabetes Comorbidities and Treatment Challenges: Rationale for DPP-4 Inhibitors
Priscilla A. Hollander, Pamela R. Kushner · 2010 · Postgraduate Medicine
Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials
André Jacques Scheen · 2020 · Diabetes & Metabolism
Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial
Priscilla A. Hollander, Katarı́na Rašlová, Trine Vang Skjøth, Jacob Råstam, Joanne Liutkus · 2010 · Diabetes Obesity and Metabolism
Emerging diabetes therapies and technologies
Emily G. Moser, Audrey A. Morris, Satish K. Garg · 2012 · Diabetes Research and Clinical Practice
Costs and Consequences Associated With Newer Medications for Glycemic Control in Type 2 Diabetes
Anushua Sinha, Mangala Rajan, Thomas J. Hoerger, Len Pogach · 2010 · Diabetes Care
Cardiometabolic effects of a new class of antidiabetic agents
Desouza, Cyrus V., Gupta, Namita, Patel, Anery · 2015 · Clinical Therapeutics
Safety, Efficacy, and Bioavailability of Fixed-Dose Combinations in Type 2 Diabetes Mellitus: A Systematic Updated Review
T Vijayakumar, Jayasutha Jayram, Meghana Cheekireddy, Dasari Himaja, Yalamanchili Dharma Teja, Damodharan Narayanasamy · 2017 · Current Therapeutic Research
Efficacy and safety of sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors as monotherapy or add‐on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta‐analysis
Zhiying Wang, Jiahui Sun, Ruobing Han, Dongzhu Fan, Xinyi Dong, Zenghui Luan, Rongwu Xiang, Mingyi Zhao, Jingyu Yang · 2017 · Diabetes Obesity and Metabolism
Efficacy and Safety of Incretin-Based Therapies in Patients with Type 2 Diabetes Mellitus
Matthew Philip Gilbert, Richard E. Pratley · 2009 · The American Journal of Medicine
Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes.
Richard E. Pratley · 2008 · PubMed Central
Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes
Kun‐Ho Yoon, Gerald Shockey, Rujun Teng, Gregory T. Golm, Purav Thakkar, A G Meehan, Debora Williams‐Herman, Keith D. Kaufman, John M. Amatruda, Helmut O. Steinberg · 2011 · International Journal of Clinical Practice
A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents
Leann Olansky, Charles A. Reasner, Thomas L. Seck, Debora Williams‐Herman, M. Chen, Lisa Terranella, A. Mehta, Keith D. Kaufman, B. J. Goldstein · 2011 · Diabetes Obesity and Metabolism
Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
Bo Åhrén · 2010 · Diabetes Metabolic Syndrome and Obesity
Incretin‐Based Therapies for Type 2 Diabetes Mellitus: Current Status and Future Prospects
Scott R. Drab · 2010 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
Incretin agents in type 2 diabetes.
Stuart A. Ross, Jean-Marie Ékoé · 2010 · PubMed Central
New treatments in type 2 diabetes: a focus on the incretin‐based therapies
Anthony H Barnett · 2008 · Clinical Endocrinology
Restoration of the insulinotropic effect of glucose‐dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase‐4 inhibitors
Kasper Aaboe, S. Akram, Carolyn Fiona Deacon, Jens Juul Holst, Sten Madsbad, Thure Krarup · 2014 · Diabetes Obesity and Metabolism
The Effects of Pharmacologic Agents for Type 2 Diabetes Mellitus on Body Weight
Xavier Pi-Sunyer · 2008 · Postgraduate Medicine
Efficacy of dipeptidyl‐peptidase‐4 inhibitors and impact on β‐cell function in A sian and C aucasian type 2 diabetes mellitus patients: A meta‐analysis在亚洲人和白种人的2型糖尿病患者中DPP‐4抑制剂的疗效及对β细胞功能的影响：一项meta分析
Xiaoling Cai, Xueyao Han, Yingying Luo, Linong Ji · 2014 · Journal of Diabetes
Combination therapy of dipeptidyl peptidase‐4 inhibitors and metformin in type 2 diabetes: rationale and evidence
Yunfeng Liu, Tianpei Hong · 2013 · Diabetes Obesity and Metabolism
Initial therapy with the fixed‐dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes
Julio Wainstein, Leonid Katz, Samuel S. Engel, L. Xu, Gregory T. Golm, Shehla Hussain, Edward A. O’Neill, Keith D. Kaufman, B. J. Goldstein · 2011 · Diabetes Obesity and Metabolism
Efficacy and safety of initial combination therapy in treatment-naïve type 2 diabetes patients: a systematic review and meta-analysis
Cai, Xiaoling, Gao, Xueying, Yang, Wenjia, Han, Xueyao, Ji, Linong · 2018 · Diabetes Therapy
Current Antidiabetic Drugs
Hossain, Md. Akil, Pervin, Rokeya · 2018 · Nutritional and Therapeutic Interventions for Diabetes and Metabolic Syndrome
Pharmaceutical application and development of fixed-dose combination: dosage form review
Dong‐Wook Kim, Kwon-Yeon Weon · 2021 · Journal of Pharmaceutical Investigation
The cardiovascular safety of incretin-based therapies: a review of the evidence
John R. Petrie · 2013 · Cardiovascular Diabetology
Update on the management of diabetes in long-term care facilities
Thaer Idrees, IRIS A. CASTRO-REVOREDO, Alexandra L. Migdal, EMMELIN MARIE MORENO, Guillermo E. Umpierrez · 2022 · BMJ Open Diabetes Research & Care
Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study
Soo Kyung Lim, Jee Hyun An, Hayley Shin, Ah Reum Khang, Yenna Lee, Hwa Young Ahn, Ji Won Yoon, Seon Mee Kang, Sung Hee Choi, Young Min Cho et al. · 2011 · Clinical Endocrinology
Extra‐pancreatic effects of incretin‐based therapies: potential benefit for cardiovascular‐risk management in type 2 diabetes
Renate E. van Genugten, Diane L. Möller-Goede, Daniël H. van Raalte, Michaëla Diamant · 2012 · Diabetes Obesity and Metabolism
Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials
Xiafei Lyu, Xiaolin Zhu, Bin Zhao, Liang Du, Dawei Chen, Chun Wang, Guanjian Liu, Xingwu Ran · 2017 · Scientific Reports
Sitagliptin: a review
SREEVIDYA K. SUBBARAYAN, Mark S. Kipnes · 2011 · Expert Opinion on Pharmacotherapy
Overview of the Gliptin Class (Dipeptidyl Peptidase-4 Inhibitors) in Clinical Practice
Nancy J.V. Bohannon · 2009 · Postgraduate Medicine
Counterion Affects Interaction with Interfaces: The Antidiabetic Drugs Metformin and Decavanadate
Aungkana Chatkon, Pabitra B. Chatterjee, Myles A. Sedgwick, Kenneth J. Haller, Debbie C. Crans · 2013 · European Journal of Inorganic Chemistry
DPP-4 Inhibitors in Clinical Practice
Anna I. Palalau, Abd A. Tahrani, Milan K. Piya, Anthony H Barnett · 2009 · Postgraduate Medicine
New combination treatments in the management of diabetes: focus on sitagliptin – metformin
Jennifer Green · 2008 · Vascular Health and Risk Management
The effect of senofilcon A contact lenses compared to habitual contact lenses on ocular discomfort during exposure to a controlled adverse environment
George W Ousler, Russell T. Anderson, Kathrine E Osborn · 2007 · Current Medical Research and Opinion
Quantitative Model of the Relationship Between Dipeptidyl Peptidase‐4 (DPP‐4) Inhibition and Response: Meta‐Analysis of Alogliptin, Saxagliptin, Sitagliptin, and Vildagliptin Efficacy Results
John P. Gibbs, Jill O. Fredrickson, Todd Barbee, Itzela Correa, Brian P. Smith, Shao‐Lee Lin, Megan A. Gibbs · 2012 · The Journal of Clinical Pharmacology
Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials
Liyun He, Jialu Wang, Fan Ping, Na Yang, Jingyue Huang, Wei Li, Lingling Xu, Huabing Zhang, Yuxiu Li · 2022 · BMJ
Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo‐controlled 54‐week trial in patients with type 2 diabetes (一项为期54周的对持续使用二甲双胍与罗格列酮联合治疗的2型糖尿病患者加用西格列汀治疗的有效性与安全性的随机安慰剂对照研究)*
Adrian Sandra Dobs, Barry J. Goldstein, Pablo J. Aschner, Edward S. Horton, Guillermo E. Umpierrez, Lorraine DURAN, Julie S. HILL, Yu Chen, Gregory T. Golm, Ronald B. Langdon et al. · 2012 · Journal of Diabetes
Cardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials
Islam Y. Elgendy, Ahmed N. Mahmoud, Amr F. Barakat, Akram Y. Elgendy, Marwan S Saad, Ahmed Abu‐Zaid, Siddarth A. Wayangankar, Anthony A. Bavry · 2016 · American Journal of Cardiovascular Drugs
Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus
Tomoyuki Katsuno, Hiroki Ikeda, Kenichi Ida, Jun‐ichiro Miyagawa, Mitsuyoshi Namba · 2013 · Endocrine Journal
Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes
Cristina Bianchi, Giuseppe Daniele, Angela Dardano, Roberto Miccoli, Stefano Del Prato · 2017 · Drugs
Impact of Sitagliptin on Markers of β-cell Function: A Meta-Analysis
Daniel M. Riche, Honey E. East, Krista D. Riche · 2009 · The American Journal of the Medical Sciences
Efficacy and Safety of Incretin-Based Therapies in Patients with Type 2 Diabetes Mellitus
Matthew Philip Gilbert, Richard E. Pratley · 2009 · European Journal of Internal Medicine
Effect of initial combination therapy with sitagliptin and metformin on β ‐cell function in patients with type 2 diabetes
Debora Williams‐Herman, Lei Xu, Rujun Teng, Gregory T. Golm, J. RANDOLPH JOHNSON, Michael J. Davies, Keith D. Kaufman, B. J. Goldstein · 2011 · Diabetes Obesity and Metabolism
Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential
Nasser E. Mikhail · 2008 · Vascular Health and Risk Management
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
David M. Nathan, John B. Buse, Mayer B. Davidson, Ele Ferrannini, Rury R. Holman, Robert Sherwin, Bernard Zinman · 2009 · Diabetes Spectrum
Clinical Approaches to Preserve β-Cell Function in Diabetes
BERNARDO LEO WAJCHENBERG · 2010 · Advances in experimental medicine and biology
Potential for combination of dipeptidyl peptidase‐4 inhibitors and sodium‐glucose co‐transporter‐2 inhibitors for the treatment of type 2 diabetes
M. D. Sharma · 2015 · Diabetes Obesity and Metabolism
Incretin based therapies: A novel treatment approach for non-alcoholic fatty liver disease
Kristina Blaslov · 2014 · World Journal of Gastroenterology
Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes
Armando Pérez Monteverde, Thomas L. Seck, L. Xu, M. A. Lee, Christine McCrary Sisk, Debora Williams‐Herman, Samuel S. Engel, Keith D. Kaufman, B. J. Goldstein · 2011 · International Journal of Clinical Practice
Safety of Sitagliptin in Elderly Patients with Type 2 Diabetes: A Pooled Analysis of 25 Clinical Studies
Elizabeth Round, Samuel S. Engel, Gregory T. Golm, Michael J. Davies, Keith D. Kaufman, Barry J. Goldstein · 2014 · Drugs & Aging
Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation?
Michael Albrecht Nauck, O. Baranov, Robert A. Ritzel, Juris Jendrik Meier · 2013 · Diabetologia
Pharmacological management of type 2 diabetes: the potential of incretin‐based therapies
Bernard H. Charbonnel, Bertrand Cariou · 2010 · Diabetes Obesity and Metabolism
One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice
Kathryn Aston‐Mourney, Shoba L. Subramanian, Sakeneh Zraika, Thanya Samarasekera, Daniel T. Meier, Lynn C. Goldstein, Rebecca L. Hull · 2013 · American Journal of Physiology-Endocrinology and Metabolism
The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes
Diethelm Tschöpe, M Hanefeld, Juris Jendrik Meier, Anselm Kai Gitt, Martin Halle, Peter Bramlage, Petra‐Maria Schumm‐Draeger · 2013 · Cardiovascular Diabetology
Glucocorticoids mobilize macrophages by transcriptionally up-regulating the exopeptidase DPP4
Diaz-Jimenez, David, Petrillo, Maria Grazia, Busada, Jonathan T., Hermoso, Marcela A., Cidlowski, John A. · 2020 · Journal of Biological Chemistry
TAK ‐875, a GPR 40/ FFAR 1 agonist, in combination with metformin prevents progression of diabetes and β ‐cell dysfunction in Z ucker diabetic fatty rats
Ryo Ito, Yoshiyuki Tsujihata, K Matsuda‐Nagasumi, Ikuo Mori, N Negoro, Koji Takeuchi · 2013 · British Journal of Pharmacology
Comparative studies of dipeptidyl peptidase 4 inhibitor vs sulphonylurea among Muslim Type 2 diabetes patients who fast in the month of Ramadan: A systematic review and meta-analysis
Huai Heng Loh, Anne Yee, Huai Seng Loh, Norlela Sukor, Nor Azmi Kamaruddin · 2015 · Primary care diabetes
Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studies
Asres Berhan, Yifru Berhan · 2013 · BMC Endocrine Disorders
Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents
Chunjun Li, Xiao-Juan Liu, Lian Bai, Qian Yu, Qiu-Mei Zhang, Pei Yu, Demin M. Yu · 2014 · Diabetology & Metabolic Syndrome
A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus
Jorge Luiz Gross, James Allen Rogers, Daniel G. Polhamus, William R. Gillespie, Christian Friedrich, Yan Gong, Brigitta U. Monz, Sanjay Dhanji Patel, Alexander Staab, Silke Retlich · 2013 · BMJ Open
Dipeptidyl Peptidase-4 as a New Target of Action for Type 2 Diabetes Mellitus: A Systematic Review
Javaid H. Wani, Jennifer John‐Kalarickal, Vivian Andrew Fonseca · 2008 · Cardiology Clinics
The Placement of DPP-4 Inhibitors in Clinical Practice Recommendations for the Treatment of Types 2 Diabetes
Jaime A. Davidson · 2013 · Endocrine Practice
Metabolic surgery—principles and current concepts
Markus Gass, Christoph Beglinger, Ralph Peterli · 2011 · Langenbeck s Archives of Surgery
Obesity may attenuate the HbA1c‐lowering effect of sitagliptin in Japanese type 2 diabetic patients
Yoshiyuki Bando, Hideo Kanehara, Keiko Aoki, Azusa Hisada, Daisyu Toya, Nobuyoshi Tanaka · 2011 · Journal of Diabetes Investigation
Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co‐administered to Chinese patients with type 2 diabetes mellitus
Linong Ji, Ping Han, Xiaoyue Wang, Jingdong Liu, Shaoxiong Zheng, Ying‐Ming Jou, Edward A. O’Neill, Gregory T. Golm, Samuel S. Engel, Keith D. Kaufman et al. · 2016 · Journal of Diabetes Investigation
Initial Combination Therapy in Type 2 Diabetes
Ji Yoon Kim, Nam Hoon Kim · 2023 · Endocrinology and Metabolism
A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control
Robert Geoffrey Moses, Elizabeth Round, Yue Shentu, Gregory T. Golm, Edward A. O’Neill, Ira Gantz, Samuel S. Engel, Keith D. Kaufman, Barry J. Goldstein · 2015 · Journal of Diabetes
A randomized clinical trial of the efficacy and safety of sitagliptin as initial oral therapy in youth with type 2 diabetes
R. Ravi Shankar, Philip Scott Zeitler, Asma Deeb, Muhammad Yazid Jalaludin, Raymundo Garcia, Ron S. Newfield, Ю. Г. Самойлова, Carmen A. Rosario, Naim Shehadeh, Chandan Saha et al. · 2021 · Pediatric Diabetes
Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin
André Jacques Scheen · 2010 · Expert Opinion on Drug Metabolism & Toxicology
Efficacy and safety of the addition of sitagliptin to treatment of youth with type 2 diabetes and inadequate glycemic control on metformin without or with insulin
Jalaludin, Muhammad Yazid, Deeb, Asma, Zeitler, Philip, Garcia, Raymundo, Newfield, Ron S., Samoilova, Yulia, Rosario, Carmen A., Shehadeh, Naim, Saha, Chandan K., Zhang, Yilong et al. · 2022 · Pediatric Diabetes
Comparison of liraglutide versus other incretin‐related anti‐hyperglycaemic agents
Lawrence Blonde, Eduard Montanya · 2012 · Diabetes Obesity and Metabolism